UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...

UCB and Biogen’s drug dapirolizumab pegol has met the primary endpoint of improvement in disease activity in lupus patients.

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates ...

这些药物包括：优化肿瘤抗原释放和呈递的药物（放疗，化疗，癌症疫苗，溶瘤病毒），激活共刺激分子以改善抗原呈递细胞（APCs）活性（靶向ICOS，ICOSL，OX40，CD40和CD40L的受体激动剂），以及靶向先天免疫的药物，例如：模式识别受体（PRRs）、细胞因子、自然 ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global ...

系统性红斑狼疮（Systemic Lupus Erythematosus, SLE）是一种系统性自身免疫病，以全身多系统多脏器受累、反复的复发与缓解、体内存在大量自身抗体为主要临床特点，如不及时治疗，会造成受累脏器的不可逆损害，最终导致患者死亡。

Despite treatment advances through immunotherapies, including anti-PD-1/PD-L1 therapies, the overall prognosis of non-small cell lung cancer (NSCLC) patients remains poor, underscoring the need for ...

Tuberculosis (TB) is caused by infection with the bacterial pathogen Mycobacterium tuberculosis (M.tb) in the respiratory tract. There was an estimated 10.6 million people newly diagnosed with TB, and ...

CD40 配体 (CD40L) 抗体市场调研报告呈现了全球与中国CD40 配体 (CD40L) 抗体市场规模发展趋势。2023年全球CD40 配体 (CD40L) 抗体市场规模达到71.65亿元（人民币），中国CD40 配体 (CD40L) 抗体市场规模达x.x亿元，同时报告中也给出了2023年中国CD40 配体 (CD40L) 抗体进口和 ...